NeoProfen Approved - Farmacon-IL, LLC - Treatment for Patent Ductus Arteriosus
NeoProfen is an intravenous formulation of ibuprofen lysine indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants, who are no more than 32 weeks gestational age when usual medical management is ineffective.NeoProfen (ibuprofen lysine) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.